Nikolai Tankovich

Nikolai Tankovich refers to Dr. Nikolai I. Tankovich, a distinguished innovator, researcher, and educator in the field of medical laser applications, regenerative medicine, and biotechnology. Dr. Tankovich holds an MD, an MS in Plasma Physics, and a PhD in Biophysics. He has founded and directed several corporations, leveraging his extensive intellectual property. He has over 100 U.S. and foreign patents issued and pending, and is known for his pioneering work in areas that have led to the creation of new industries.

Dr. Tankovich's significant contributions include the invention and development of the 1.54 micron Er:Glass laser for medical applications, devices for laser hair removal, laser skin peeling, and non-ablative wrinkle removal, all of which have received FDA approval and have been licensed for use. He is also recognized as the pioneer of Laser Sparing Technology, which underpins the intellectual property of the Fraxel Laser and the concept of fractional photothermolysis. More recently, he has been involved in stem cell therapies and co-invented a biodegradable microneedle device for drug delivery through StemProtein, LLC, a subsidiary of Stemedica Cell Technologies, Inc., where he serves as President and Chief Medical Officer.

In terms of patent litigation, Dr. Tankovich appears in one tracked case as a defendant. This posture, with zero plaintiff cases, indicates that he is typically not an entity that initiates patent assertion campaigns. Instead, his patents or intellectual property are being challenged.

The notable tracked case involving Dr. Tankovich is Candela Corporation et al. v. Nikolai Tankovich, filed on November 18, 2022, before the Patent Trial and Appeal Board (PTAB). This proceeding suggests that Candela Corporation is challenging the validity of one or more patents associated with Dr. Tankovich, likely related to his extensive work in laser and aesthetic medical technologies.